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Sir,
We are grateful that Rutella et al have brought their impressive
research to our attention. We regret that we were not aware of their
work prior to the submission of our other recent publication
(Reyes E et al, 1999). As they note in their letter to the Editor,
combining our investigative results suggests that rHuG-CSF
exerts, through the induction of soluble factors such as IL-1
receptor antagonist and TNF soluble receptor, a reversible
inhibitor effect on PBMC proliferation that is not due to alterations
in cell number (CD3+, CD19+, CD45+, CD14+), cytokine produc-
tion (IL-1, IL-2, IL-6, IL-10, TNF-a, or IFNg), or activation status
(HLA-DR, CD57, or IL-2 receptor a expression). Rutella et al
suggest that the decreased PBMC proliferative response to
mitogen after treatment with sera from patients treated with rHuG-
CSF is due to cell cycle arrest such that a lymphocyte partial acti-
vation phenotype becomes dominant. Interestingly, while failure
to progress through G0 is commonly due to alterations in IL-2R
expression, we found that rHuG-CSF treatment does not alter the
expression of IL-2 receptor alpha (IL-2Ra) on PBMCs. Certainly
other avenues leading to inhibition of lymphocyte cycling will
have to be explored. Our finding of an upregulation of memory
(CD45RO+) T helper cells (CD4+) with rHuG-CSF treatment with
a concomittant decline in naive (CD4+CD45RA+) subset may
explain the decreased proliferative response to mitogens, since
naive cells demonstrate greater proliferation to mitogenic stimula-
tion than do memory cells. However, this finding cannot explain
the lymphocyte cycling arrest in G0. Evaluation of the effects of
rHuG-CSF treatment on the expression of co-regulatory molecules
on antigen presenting cells may prove fruitful in elucidating the
mechanism of lymphocyte cycling arrest.
The ability of rHuG-CSF to inhibit mitogenic proliferative
responses may be proven useful clinically in inhibiting unwanted
immunologic activity such as acute graft-versus-host disease,
autoimmune disorders, as well as chronic inflammatory diseases.
Further, Rutella et al’s suggestion that rHuG-CSF results in toler-
ance induction may be exploited by coupling rHuG-CSF treatment
with specific antigens in autoimmune disorders. Certainly, more
work is needed to establish the mechanism of rHuG-CSF’s effect
on mitogenic proliferative responses, as well as testing the effect
in the context of specific antigens. Still, the previous work of
investigators such as Rutella et al, Pan et al, and Roe et al, as well
as our own, demonstrates a fruitful role for rHuG-CSF as an
immunomodulator in the context of autoimmune/allergy and
transplant medicine.
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Sir,
We read with great interest the article of Forsyth et al (1999) (Br J
Cancer 79: 1828–1835) about the role of gene expression of
matrix metalloproteinases (MMPs) in malignant gliomas. There
is a growing interest in detecting gene expression of these
components for a better understanding of molecular mechanisms
regarding tumour invasion and metastasis in malignant diseases
(Parsons et al, 1997). Therefore, sensitive and specific molecular
biological methods are required but they are mostly user orientated
and hardly standardized.
We are investigating the molecular biology of prostate cancer, in
particular MMPs and their tissue inhibitors, by real-time RT-PCR
(Wittwer et al, 1997). Applying the primers for MMP-2 (also
named gelatinase A or collagenase IV) used by Forsyth et al for
this purpose, we experienced some disagreeable surprises which
seem important enough to us to be commented upon.